Iain B McInnes1, Koji Kato2, Marina Magrey3, Joseph F Merola4, Mitsumasa Kishimoto5, Derek Haaland6,7, Liang Chen2, Yuanyuan Duan2, Jianzhong Liu2, Ralph Lippe8, Peter Wung2. 1. College of Medical, Veterinary, and Life Sciences, Glasgow Biomedical Research Centre, University of Glasgow, 120 University Pl., Glasgow, G128QQ, UK. Iain.McInnes@glasgow.ac.uk. 2. AbbVie Inc., North Chicago, IL, USA. 3. Case Western Reserve University School of Medicine at University Hospitals, Cleveland, OH, USA. 4. Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 5. Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan. 6. McMaster University, Hamilton, ON, Canada. 7. The Waterside Clinic, Barrie, ON, Canada. 8. AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.
Abstract
INTRODUCTION: Efficacy and safety of the Janus kinase (JAK) inhibitor upadacitinib (UPA) was evaluated in patients with psoriatic arthritis (PsA) through week 104 of the ongoing long-term extension of the phase 3 trial SELECT-PsA 1. METHODS: Exploratory analyses of all primary and secondary endpoints (non-responder imputation and as observed for binary endpoints; mixed-effect model repeated measures and as observed for continuous endpoints), and summary of treatment-emergent adverse events, in patients receiving UPA 15 mg (UPA15) or 30 mg (UPA30) once daily, or adalimumab 40 mg (ADA) every other week, through week 104 are reported. RESULTS: Of 1704 patients, 25.4% discontinued the study drug by week 104. Proportions of patients achieving ≥ 20%/50%/70% improvement in American College of Rheumatology criteria (ACR20/50/70), ≥ 75%/90%/100% improvement in Psoriasis Area and Severity Index (PASI75/90/100), or minimal disease activity (MDA) were maintained through week 104; greater responses by nominal P value were observed with UPA15 and UPA30 versus ADA for ACR20/50/70 and MDA. Mean change from baseline in modified total Sharp/van der Heijde Score (mTSS) was similar across groups and to week 56 results. The safety profile of UPA was generally comparable to ADA and not altered from week 56 data. Rates of serious infection, herpes zoster, anemia, neutropenia, lymphopenia, and elevated creatine phosphokinase remained numerically higher with UPA15 and/or UPA30 versus ADA. Rates of malignancies excluding non-melanoma skin cancer (NMSC), major adverse cardiovascular events, and venous thromboembolism were similar across groups; rates of NMSC were higher with UPA versus ADA. Two deaths were reported with UPA15, one with UPA30, and one with ADA. CONCLUSIONS: In PsA patients, efficacy responses were similar or greater with UPA15 or UPA30 versus ADA through week 104, and inhibition of radiographic progression was maintained. No new safety risks were identified with exposure to UPA through 2 years (week 104). CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03104400.
INTRODUCTION: Efficacy and safety of the Janus kinase (JAK) inhibitor upadacitinib (UPA) was evaluated in patients with psoriatic arthritis (PsA) through week 104 of the ongoing long-term extension of the phase 3 trial SELECT-PsA 1. METHODS: Exploratory analyses of all primary and secondary endpoints (non-responder imputation and as observed for binary endpoints; mixed-effect model repeated measures and as observed for continuous endpoints), and summary of treatment-emergent adverse events, in patients receiving UPA 15 mg (UPA15) or 30 mg (UPA30) once daily, or adalimumab 40 mg (ADA) every other week, through week 104 are reported. RESULTS: Of 1704 patients, 25.4% discontinued the study drug by week 104. Proportions of patients achieving ≥ 20%/50%/70% improvement in American College of Rheumatology criteria (ACR20/50/70), ≥ 75%/90%/100% improvement in Psoriasis Area and Severity Index (PASI75/90/100), or minimal disease activity (MDA) were maintained through week 104; greater responses by nominal P value were observed with UPA15 and UPA30 versus ADA for ACR20/50/70 and MDA. Mean change from baseline in modified total Sharp/van der Heijde Score (mTSS) was similar across groups and to week 56 results. The safety profile of UPA was generally comparable to ADA and not altered from week 56 data. Rates of serious infection, herpes zoster, anemia, neutropenia, lymphopenia, and elevated creatine phosphokinase remained numerically higher with UPA15 and/or UPA30 versus ADA. Rates of malignancies excluding non-melanoma skin cancer (NMSC), major adverse cardiovascular events, and venous thromboembolism were similar across groups; rates of NMSC were higher with UPA versus ADA. Two deaths were reported with UPA15, one with UPA30, and one with ADA. CONCLUSIONS: In PsA patients, efficacy responses were similar or greater with UPA15 or UPA30 versus ADA through week 104, and inhibition of radiographic progression was maintained. No new safety risks were identified with exposure to UPA through 2 years (week 104). CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03104400.
Authors: Josef S Smolen; Aileen L Pangan; Paul Emery; William Rigby; Yoshiya Tanaka; Juan Ignacio Vargas; Ying Zhang; Nemanja Damjanov; Alan Friedman; Ahmed A Othman; Heidi S Camp; Stanley Cohen Journal: Lancet Date: 2019-05-23 Impact factor: 79.321
Authors: Roy Fleischmann; Aileen L Pangan; In-Ho Song; Eduardo Mysler; Louis Bessette; Charles Peterfy; Patrick Durez; Andrew J Ostor; Yihan Li; Yijie Zhou; Ahmed A Othman; Mark C Genovese Journal: Arthritis Rheumatol Date: 2019-08-28 Impact factor: 10.995
Authors: Désirée van der Heijde; In-Ho Song; Aileen L Pangan; Atul Deodhar; Filip van den Bosch; Walter P Maksymowych; Tae-Hwan Kim; Mitsumasa Kishimoto; Andrea Everding; Yunxia Sui; Xin Wang; Alvina D Chu; Joachim Sieper Journal: Lancet Date: 2019-11-12 Impact factor: 79.321
Authors: Gerd R Burmester; Joel M Kremer; Filip Van den Bosch; Alan Kivitz; Louis Bessette; Yihan Li; Yijie Zhou; Ahmed A Othman; Aileen L Pangan; Heidi S Camp Journal: Lancet Date: 2018-06-18 Impact factor: 79.321
Authors: Mark C Genovese; Roy Fleischmann; Bernard Combe; Stephen Hall; Andrea Rubbert-Roth; Ying Zhang; Yijie Zhou; Mohamed-Eslam F Mohamed; Sebastian Meerwein; Aileen L Pangan Journal: Lancet Date: 2018-06-18 Impact factor: 79.321
Authors: Denis Poddubnyy; Deepak R Jadon; Filip Van den Bosch; Philip J Mease; Dafna D Gladman Journal: Semin Arthritis Rheum Date: 2021-06-19 Impact factor: 5.532
Authors: Roy Fleischmann; Eduardo Mysler; Louis Bessette; Charles G Peterfy; Patrick Durez; Yoshiya Tanaka; Jerzy Swierkot; Nasser Khan; Xianwei Bu; Yihan Li; In-Ho Song Journal: RMD Open Date: 2022-02